MAIA Biotechnology, Inc. (MAIA)

1.37 0.04 (2.83%)

As of 2026-04-02 18:44:57 EST

MAIA Biotechnology, Inc. is a public, immune-oncology company based in Chicago, IL focused on the development of telomere targeting agents for the treatment of telomerase-positive cancer cells.

Traded asNYSE: MAIA
ISINUS5526411021
CIK0001878313
LEI—
EIN—
Sector—
IndustryPharmaceutical Preparations
CEOVlad Vitoc
Employees—
Fiscal Year End1231
Address444 WEST LAKE STREET, SUITE 1700, CHICAGO, IL, 60606
Phone312-416-8592
Websitehttps://maiabiotech.com/
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
MAIAMAIA Biotechnology, Inc.2026-04-02 18:44:571.370.042.83
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
MAIA0001878313MAIA Biotechnology, Inc.US5526411021——NYSE2834Pharmaceutical Preparations1231DE444 WEST LAKE STREET, SUITE 1700CHICAGOIL60606UNITED STATESUS312-416-8592444 WEST LAKE STREET, SUITE 1700, CHICAGO, IL, 60606444 WEST LAKE STREET, SUITE 1700, CHICAGO, IL, 60606———Vlad Vitoc—https://maiabiotech.com/48,948,79538,624,28960,671,491MAIA Biotechnology, Inc. is a public, immune-oncology company based in Chicago, IL focused on the development of telomere targeting agents for the treatment of telomerase-positive cancer cells.2026-04-02 19:25:50
This is a preview of the latest data. Subscribe to access the full data.
MAIA Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
MAIA Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
202548,948,795-18,514,505-27.443860,671,49131,084,177105.0591
202467,463,30044,979,100200.047629,587,3149,584,48847.9157
202322,484,20022,484,20010020,002,8269,006,42281.9033
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Sergei GryaznovChief Scientific Officer2024363,000145,200——13,461929,838
Vlad VitocPresident, Chief Executive Officer2024473,000236,500——13,4611,360,441
Joseph F. McguireChief Financial Officer2023284,1670——96,431844,814
Sergei GryaznovChief Scientific Officer2023363,0000——54,334894,749
Vlad VitocPresident, Chief Executive Officer2023473,0000——56,8231,430,757
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
202513
202413
202313
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue—00
Cost Of Revenue———
Gross Profit———
Research And Development Expenses453,74510,009,22911,112,257
General And Administrative Expenses9,722,3546,947,9819,070,124
Operating Expenses24,269,68616,957,21020,182,381
Operating Income-24,269,686-16,957,210-20,182,381
Net Income-22,396,172-23,254,656-19,772,905
Earnings Per Share Basic-0.7-1.05-1.49
Earnings Per Share Diluted-0.7-1.05-1.49
Weighted Average Shares Outstanding Basic32,114,60822,197,51713,261,572
Weighted Average Shares Outstanding Diluted32,114,60822,197,51713,261,572
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents000
Marketable Securities Current———
Accounts Receivable———
Inventories———
Non Trade Receivables———
Other Assets Current———
Total Assets Current9,701,85610,152,4797,564,052
Marketable Securities Non Current———
Property Plant And Equipment———
Other Assets Non Current2,8002,8002,800
Total Assets Non Current2,8002,8002,800
Total Assets9,704,65610,155,2797,566,852
Accounts Payable2,038,8031,512,4361,638,546
Deferred Revenue———
Short Term Debt———
Other Liabilities Current3,797,5952,317,6023,298,607
Total Liabilities Current5,836,3983,830,0384,937,153
Long Term Debt———
Other Liabilities Non Current———
Total Liabilities Non Current1,492,3952,690,6052,152,188
Total Liabilities7,328,7936,520,6437,089,341
Common Stock3,8632,6161,699
Retained Earnings-109,631,005-87,234,833-63,980,177
Accumulated Other Comprehensive Income-50,228-30,615-16,260
Total Shareholders Equity2,375,8633,634,636477,511
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization———
Share Based Compensation Expense2,631,6521,912,7443,089,304
Other Non Cash Income Expense———
Change In Accounts Receivable——-158,405
Change In Inventories———
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable519,720-118,827471,897
Change In Other Liabilities1,478,955-979,7922,169,921
Cash From Operating Activities-18,844,598-15,704,461-13,071,016
Purchases Of Marketable Securities———
Sales Of Marketable Securities———
Acquisition Of Property Plant And Equipment———
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities—-21,545-117
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock327,6152,920,696—
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities17,906,54718,176,6099,270,901
Change In Cash—2,450,603-3,800,232
Cash At End Of Period000
Income Taxes Paid3——
Interest Paid—576,863
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share-0.7-1.05-1.49
Price To Earnings Ratio-2.1857-1.8857-0.7852
Earnings Growth Rate-33.3333-29.5302-14.8571
Price Earnings To Growth Ratio0.06560.06390.0529
Book Value Per Share0.0740.16370.036
Price To Book Ratio20.681112.092332.4936
Ebitda———
Enterprise Value———
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio———
Capital Expenditures———
Free Cash Flow———
Return On Equity-9.4265-6.3981-41.4083
One Year Beta0.69621.13650.8427
Three Year Beta0.82310.53390.3022
Five Year Beta0.59520.53390.3022
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Louie Ngar YeeDirector2026-03-3133,748A33,748
Guerrero RamiroDirector2026-03-3127,258A27,258
CHAOUKI STEVEN MDirector2026-03-3127,907A27,907
Smith StanDirector2026-03-3133,099A33,099
Theagene Jean-ManasseDirector2026-03-3127,258A27,258
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
BANK OF AMERICA CORP /DE/2025-12-3146301.5333
Creative Planning2025-12-3144,09828,8221.53
JONES FINANCIAL COMPANIES LLLP2025-12-313492281.5307
NORTHERN TRUST CORP2025-12-3159,71939,0321.53
OSAIC HOLDINGS, INC.2025-12-3112,7508,3341.5299
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
VANGUARD INDEX FUNDS2025-12-31Institutional Select SharesVSTSX586,640897,559.20.0
VANGUARD INDEX FUNDS2025-12-31Institutional Plus SharesVSMPX586,640897,559.20.0
VANGUARD INDEX FUNDS2025-12-31ETF SharesVTI586,640897,559.20.0
VANGUARD INDEX FUNDS2025-12-31Institutional SharesVITSX586,640897,559.20.0
VANGUARD INDEX FUNDS2025-12-31Admiral SharesVTSAX586,640897,559.20.0
This is a preview of the latest data. Subscribe to access the full data.